- Previous Close
3.5900 - Open
3.6700 - Bid --
- Ask --
- Day's Range
3.6700 - 3.6700 - 52 Week Range
3.0300 - 14.8000 - Volume
1,126 - Avg. Volume
39,695 - Market Cap (intraday)
3.355M - Beta (5Y Monthly) 1.28
- PE Ratio (TTM)
-- - EPS (TTM)
-5.2300 - Earnings Date May 13, 2025 - May 19, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder. The company was founded in 1991 and is based in South San Francisco, California.
www.titanpharm.comRecent News: TTNP
View More
Performance Overview: TTNP
Trailing total returns as of 4/11/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TTNP
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TTNP
View MoreValuation Measures
Market Cap
3.36M
Enterprise Value
-2.77M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.38
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-51.74%
Return on Equity (ttm)
-103.63%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-4.71M
Diluted EPS (ttm)
-5.2300
Balance Sheet and Cash Flow
Total Cash (mrq)
2.83M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-2.07M